Predicting survival in malignant mesothelioma Source: Eur Respir J 2011; 38: 1420-1424 Year: 2011
Predicting survival in mesothelioma Source: Eur Respir J 2012; 40: 1582 Year: 2012
PET predicts survival in malignant pleural mesothelioma Source: ISSN=ISSN 1810-6838, ISBN=, page=290 Year: 2007
Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Malignant pleural mesothelioma (MPM): clinical presentation, complications and survival Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007
Clinical characteristics, treatment and survival outcomes in malignant mesothelioma Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012
Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003
Malignant pleural mesothelioma clinical aspects and survival in 93 cases Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005
Malignant mesothelioma and chemotherapy: efficacy and influence on survival of patients Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients Source: Annual Congress 2009 - Preoperative functional assessment and surgery for malignant diseases Year: 2009
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma Source: Eur Respir J , 49 (3) 1601428; DOI: 10.1183/13993003.01428-2016 Year: 2017
Is comorbidity a good prognostic factor for malignant pleural mesothelioma? Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer Source: Annual Congress 2005 - What's new in the pleura Year: 2005
Relationship between baseline metabolic 18F-FDG parameters and survival in malignant pleural mesothelioma: A single centre experience Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018
Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018